Latest Alere Inc (ALR) Headlines
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017
M2 - Tue Mar 11, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nc4zfn/in_vitro) has announced the addition of the "Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017" report to their offering. The in vitro diagnostic market studied in this report has been segmented by technology, product type, application, end user, and geography. The technology market is further segmented into clinical chemistry, immunochemistry, molecular diagnostics, hematology, coagulation, microbiology, and others, of which immunochemistry accounted for the largest share with 25.8% in 2010. By product type, the IVD market has segments like instruments, reagents, data management software/hardware, and services. Based on applications, the in vitro diagnostic market is segmented as diabetes, infectious diseases, oncology, cardiology, nephrology, auto-immune diseases, AIDS, drug testing, and others. Laboratory testing, hospital testing, academic (AMCs and university) testing, point-of-care testing, patient self-testing, and others comprise the end-user segment of the IVD market. The global in vitro diagnostic market was valued at $49.2 billion in 2012 and is expected to reach $69.1 billion by 2017, at a CAGR of 7% from 2012 to 2017. The IVD market is primarily driven by rising incidences of chronic and infectious diseases in emerging economies, a rapidly aging population, the rise in point-of-care testing, and the rising importance of personalized medicine. However, factors such as stringent regulatory frameworks and a shortage of budget and labor are restraining the growth of the market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global In Vitro Diagnostic Market, By Technique 5 Global In Vitro Diagnostic Market, By Product Type 6 Global In Vitro Diagnostic Market, By Application 7 Global In Vitro Diagnostic Market, By End-User 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc - Alere, Inc - Arkray, Inc - Bayer AG - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc - Biomerieux - Danaher Corporation - Diagnostica Stago Sas - Diasorin SPA - Hologic, Inc - Horiba, Ltd - Johnson & Johnson - Novartis International Ag - Qiagen NV - Roche Diagnostics Limited - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific, Inc For more information visit http://www.researchandmarkets.com/research/nc4zfn/in_vitro
Coagulation Home Testing Improves Outcomes among Atrial Fibrillation Patients on Warfarin Therapy and Enhances Clinical Efficiency, According to New Study
PR Newswire - Tue Mar 04, 3:30PM CST
Alere Inc. (NYSE: ALR), a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, today announced the results of a study demonstrating that at-home coagulation testing among atrial fibrillation patients receiving warfarin led to improved outcomes versus traditional self-testing management, as well as enhanced clinical efficiencies and reduced costs. Results of the study, which was supported by Alere, were published today in the current issue of the journal Nursing 2014.
Alere Inc. Declares Cash Dividend On Its Series B Convertible Perpetual Preferred Stock
PR Newswire - Mon Mar 03, 6:33PM CST
Alere Inc. (NYSE: ALR), a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B). The dividend is payable on April 15, 2014 to holders of record of Series B stock at the close of business on April 1, 2014.
Global Enteric Disease Testing Market 2014-2018: New Emerging Viruses and Bacteria Playing an Important Role in Diagnostics Industry
M2 - Wed Feb 26, 6:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/lrghlr/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018" report to their offering. The analysts forecast the Global Enteric Disease Testing market to grow at a CAGR of 2.83 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of enteric diseases. The Global Enteric Disease Testing market has also been witnessing the emergence of new pathogens causing infections. However, the stringent regulatory approval could pose a challenge to the growth of this market. Key vendors dominating this space are Alere Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Cepheid Inc. and DiaSorin S.p.A. Other vendors mentioned in the report are Affymetrix Inc., Beckton, Dickenson and Co., Biomerica Inc., Coris BioConcept, Danaher Corp., Meridian Bioscience Inc., Quest Diagnostics Inc., R-Biopharm AG, and Trinity Biotech PLC. Commenting on the report, an analyst from the team said: Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. According to the report, one of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. For more information visit http://www.researchandmarkets.com/research/lr...al_enteric About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Alere to Attend Upcoming Financial Conferences
PR Newswire - Mon Feb 24, 3:30PM CST
Alere Inc. (NYSE: ALR), the world's leading provider of point-of-care rapid diagnostic and health information solutions, announced today that it will attend three separate financial conferences over the next two weeks. Jon Russell, Vice President, Finance, will attend and present at all three events. Conference information and presentation schedule are as follows:
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Thursday
Alere to Showcase its Connected Health Technologies at HIMSS 2014
PR Newswire - Wed Feb 19, 7:30AM CST
Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health through the merger of rapid diagnostics and health information solutions, today announced that Alere will demonstrate its Connected Health technologies at the HIMSS 2014 Annual Conference to help providers, payers and accountable care organizations improve care coordination, identify gaps in care, and drive healthy patient behaviors. The conference, held at the Orange County Convention Center in Orlando, FL from February 23 - 27, 2014, brings together over 37,000 healthcare IT professionals, clinicians, executives and leading HIT companies from around the world. During the conference, Alere will be showcasing the Company's suite of Connected Health solutions at booth #5345.
Alere Earnings Beat, EPS Rises 20% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 10:00AM CST
For full year 2013, Alere revealed a 5.3% rise in net earnings to $2.19 per share from $2.08 per share a year ago
Alere (ALR) in Focus: Stock Tumbles 8.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 7:59AM CST
Alere Inc. (ALR) saw a big move last session, breaking the recent trend of the company, as the stock is now trading below the volatile price range of $35.67 to $33.99 in the past one-month time frame.
NYSE stocks posting largest volume increases
AP - Thu Feb 06, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
NYSE stocks posting largest percentage decreases
AP - Thu Feb 06, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
Trade-Ideas: Alere (ALR) Is Today's "Water-Logged And Getting Wetter" Stock
at The Street - Thu Feb 06, 8:53AM CST
Trade-Ideas LLC identified Alere (ALR) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Alere Inc. Announces Fourth Quarter 2013 Results
PR Newswire - Thu Feb 06, 6:30AM CST
Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health information solutions, today announced its financial results for the quarter ended December 31, 2013.
Miraculins and Alere Shift Focus of Endoglin Program from Sub-License to Supply Agreement
Marketwire - Thu Jan 30, 6:52PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces today that Alere Inc. ("Alere") has elected not to proceed further in the direct commercial development of a professional diagnostic product for the biomarker Endoglin, but instead will support Miraculins in seeking commercialization opportunities for Endoglin by supplying key antibodies that were developed by Alere. As part of this decision, Alere has declined to proceed further with its Endoglin license from Miraculins and the parties have agreed to work to enhance Miraculins' rights to receive a secure supply of high quality, proprietary Endoglin reagents manufactured by Alere.
Alere Inc. Schedules Conference Call for 8:30 a.m. ET February 6, 2014 to Discuss Fourth Quarter 2013 Results
PR Newswire - Thu Jan 30, 7:00AM CST
Alere Inc. (NYSE:ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health information solutions, today announced that it will release its fourth quarter 2013 earnings on Thursday, February 6, 2014. The Company will also host a conference call beginning at 8:30 a.m. (Eastern Time) on that date to discuss these results and other corporate matters. During the conference call, the Company will discuss and answer questions concerning business and financial developments and trends. The Company's responses to questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been disclosed previously.
First Rapid Molecular Diagnostic Test to Detect Influenza A and B Virus in Under 15 Minutes Now Available in Europe on the Alere i Platform
PR Newswire - Thu Jan 23, 11:30AM CST
Alere Inc. (NYSE: ALR), a leading global provider of point-of-care rapid diagnostic and health information solutions, today announced the availability in Europe of the Alere i Influenza A & B test, the first and only molecular test to detect and differentiate influenza A and B virus in less than 15 minutes. The test is now commercially available in Austria, France, Spain, Switzerland, Germany, Italy and the UK.
Do You Know How to Read a Report Card?
by Charles Ekyagonza - All Africa Global Media - Fri Jan 17, 1:44AM CST
At the end of every term, learners are given report cards as a way of evaluating their work and behaviour during the term.
Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019
M2 - Wed Mar 12, 3:58AM CDT
Research and Markets (http://www.researchandmarkets.com/research/mdgmns/rapid_medical) has announced the addition of the "Rapid Medical Diagnostic Kits Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2013 - 2019" report to their offering. The rapid medical diagnostic kits market is experiencing impressive growth globally because of the continuous increase in demand for preventive management of infectious diseases. Since its introduction, rapid medical diagnostic kits are becoming a vital part of the medical diagnostics industry and the scope of this market has been perpetually increasing in terms of detectable diseases and adoption by end users. This report studies the global market for rapid diagnostic kits through three major perspectives namely, application areas, technologies and geography. The application segment of this market has been further segmented into three sub-divisions namely clinical testing, home-use and veterinary diagnostics. In addition, the technology segment of rapid medical diagnostic kits market has been categorized into lateral flow, flow-through, agglutination assays and solid phase. Each of the above segments are analyzed on the basis of their market size (in terms of USD million) for the period 2011 to 2019. This also includes the forecast of the market segments in terms of CAGR (%) for the period 2013 - 2019, considering 2012 as the base year. Geographically, the rapid medical diagnostic kits market is categorized into four regions namely, North America, Europe, Asia-Pacific and Rest of the World (RoW). The market revenues (for the period 2011 - 2019) and forecast (for the period 2013 - 2019) for each of these regions have been included in this report. The market overview section of the report demonstrates the qualitative analysis of the market dynamics of the global rapid medical diagnostic kits market and thus includes information about the drivers, restraints, opportunities, Porter's five forces model and market attractiveness analysis of this industry. Key Topics Covered: Introduction Executive Summary Rapid Medical Diagnostic Kits Market Overview Global Rapid Medical Diagnostic Kits Market, by Applications, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Technology, 2011 - 2019 (USD Million) Global Rapid Medical Diagnostic Kits Market, by Geography, 2011 - 2019, (USD Million) Recommendations Competitive Landscape Companies Mentioned - Abaxis, Inc. - Abbott Laboratories, Inc. - Alere, Inc. - Becton, Dickinson & Company - Bio-Rad Laboratories, Inc. - Danaher Corporation (Beckman Coulter) - MegaCor Diagnostik GmbH - F. Hoffmann-La Roche Ltd. - Trinity Biotech plc - Zoetis, Inc. For more information visit http://www.researchandmarkets.com/research/md...id_medical About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017
M2 - Tue Mar 11, 6:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/nc4zfn/in_vitro) has announced the addition of the "Concise Analysis of the International In Vitro Diagnostic (IVD) Market - Forecast To 2017" report to their offering. The in vitro diagnostic market studied in this report has been segmented by technology, product type, application, end user, and geography. The technology market is further segmented into clinical chemistry, immunochemistry, molecular diagnostics, hematology, coagulation, microbiology, and others, of which immunochemistry accounted for the largest share with 25.8% in 2010. By product type, the IVD market has segments like instruments, reagents, data management software/hardware, and services. Based on applications, the in vitro diagnostic market is segmented as diabetes, infectious diseases, oncology, cardiology, nephrology, auto-immune diseases, AIDS, drug testing, and others. Laboratory testing, hospital testing, academic (AMCs and university) testing, point-of-care testing, patient self-testing, and others comprise the end-user segment of the IVD market. The global in vitro diagnostic market was valued at $49.2 billion in 2012 and is expected to reach $69.1 billion by 2017, at a CAGR of 7% from 2012 to 2017. The IVD market is primarily driven by rising incidences of chronic and infectious diseases in emerging economies, a rapidly aging population, the rise in point-of-care testing, and the rising importance of personalized medicine. However, factors such as stringent regulatory frameworks and a shortage of budget and labor are restraining the growth of the market. Key Topics Covered: 1 Introduction 2 Executive Summary 3 Market Overview 4 Global In Vitro Diagnostic Market, By Technique 5 Global In Vitro Diagnostic Market, By Product Type 6 Global In Vitro Diagnostic Market, By Application 7 Global In Vitro Diagnostic Market, By End-User 8 Geographic Analysis 9 Competitive Landscape 10 Company Profiles Companies Mentioned: - Abbott Laboratories, Inc - Alere, Inc - Arkray, Inc - Bayer AG - Becton, Dickinson And Company - Bio-Rad Laboratories, Inc - Biomerieux - Danaher Corporation - Diagnostica Stago Sas - Diasorin SPA - Hologic, Inc - Horiba, Ltd - Johnson & Johnson - Novartis International Ag - Qiagen NV - Roche Diagnostics Limited - Siemens Healthcare - Sysmex Corporation - Thermo Fisher Scientific, Inc For more information visit http://www.researchandmarkets.com/research/nc4zfn/in_vitro
Coagulation Home Testing Improves Outcomes among Atrial Fibrillation Patients on Warfarin Therapy and Enhances Clinical Efficiency, According to New Study
PR Newswire - Tue Mar 04, 3:30PM CST
Alere Inc. (NYSE: ALR), a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, today announced the results of a study demonstrating that at-home coagulation testing among atrial fibrillation patients receiving warfarin led to improved outcomes versus traditional self-testing management, as well as enhanced clinical efficiencies and reduced costs. Results of the study, which was supported by Alere, were published today in the current issue of the journal Nursing 2014.
Alere Inc. Declares Cash Dividend On Its Series B Convertible Perpetual Preferred Stock
PR Newswire - Mon Mar 03, 6:33PM CST
Alere Inc. (NYSE: ALR), a global leader in empowering individuals to take greater control of their health at home by connecting innovative diagnostics in the hands of patients to their healthcare providers, has declared a cash dividend of $3.00 per share on its Series B Convertible Perpetual Preferred Stock (NYSE: ALR.PR.B). The dividend is payable on April 15, 2014 to holders of record of Series B stock at the close of business on April 1, 2014.
Global Enteric Disease Testing Market 2014-2018: New Emerging Viruses and Bacteria Playing an Important Role in Diagnostics Industry
M2 - Wed Feb 26, 6:38AM CST
Research and Markets (http://www.researchandmarkets.com/research/lrghlr/global_enteric) has announced the addition of the "Global Enteric Disease Testing Market 2014-2018" report to their offering. The analysts forecast the Global Enteric Disease Testing market to grow at a CAGR of 2.83 percent over the period 2013-2018. One of the key factors contributing to this market growth is the increasing incidence of enteric diseases. The Global Enteric Disease Testing market has also been witnessing the emergence of new pathogens causing infections. However, the stringent regulatory approval could pose a challenge to the growth of this market. Key vendors dominating this space are Alere Inc., bioMerieux SA, Bio-Rad Laboratories Inc., Cepheid Inc. and DiaSorin S.p.A. Other vendors mentioned in the report are Affymetrix Inc., Beckton, Dickenson and Co., Biomerica Inc., Coris BioConcept, Danaher Corp., Meridian Bioscience Inc., Quest Diagnostics Inc., R-Biopharm AG, and Trinity Biotech PLC. Commenting on the report, an analyst from the team said: Vendors are introducing new diagnostic tests for new found pathogens that are responsible for some other types of infectious diseases. These new pathogens include West Nile virus, respiratory syncytial virus, genital mycoplasma, C. difficile, norovirus, and rotavirus. C. difficile and rotavirus tests have seen the maximum level of acceptance in the market. Thus, the improvement in detection technology aiding in the identification of new pathogens is driving the need for enteric disease testing products. According to the report, one of the major drivers in the market is the increasing incidence of enteric diseases among the population, creating a need for testing methods that effectively diagnose diseases. For more information visit http://www.researchandmarkets.com/research/lr...al_enteric About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
Alere to Attend Upcoming Financial Conferences
PR Newswire - Mon Feb 24, 3:30PM CST
Alere Inc. (NYSE: ALR), the world's leading provider of point-of-care rapid diagnostic and health information solutions, announced today that it will attend three separate financial conferences over the next two weeks. Jon Russell, Vice President, Finance, will attend and present at all three events. Conference information and presentation schedule are as follows:
Zacks Rank #5 Additions for Thursday - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Feb 20, 8:30AM CST
Here are 5 stocks added to the Zacks Rank #5 (strong sell) List for Thursday
Alere to Showcase its Connected Health Technologies at HIMSS 2014
PR Newswire - Wed Feb 19, 7:30AM CST
Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health through the merger of rapid diagnostics and health information solutions, today announced that Alere will demonstrate its Connected Health technologies at the HIMSS 2014 Annual Conference to help providers, payers and accountable care organizations improve care coordination, identify gaps in care, and drive healthy patient behaviors. The conference, held at the Orange County Convention Center in Orlando, FL from February 23 - 27, 2014, brings together over 37,000 healthcare IT professionals, clinicians, executives and leading HIT companies from around the world. During the conference, Alere will be showcasing the Company's suite of Connected Health solutions at booth #5345.
Alere Earnings Beat, EPS Rises 20% - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Feb 11, 10:00AM CST
For full year 2013, Alere revealed a 5.3% rise in net earnings to $2.19 per share from $2.08 per share a year ago
Alere (ALR) in Focus: Stock Tumbles 8.0% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Feb 07, 7:59AM CST
Alere Inc. (ALR) saw a big move last session, breaking the recent trend of the company, as the stock is now trading below the volatile price range of $35.67 to $33.99 in the past one-month time frame.
NYSE stocks posting largest volume increases
AP - Thu Feb 06, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on New York Stock Exchange at the close of trading:
NYSE stocks posting largest percentage decreases
AP - Thu Feb 06, 5:02PM CST
NEW YORK (AP) — A look at the 10 biggest percentage decliners on New York Stock Exchange at the close of trading:
Trade-Ideas: Alere (ALR) Is Today's "Water-Logged And Getting Wetter" Stock
at The Street - Thu Feb 06, 8:53AM CST
Trade-Ideas LLC identified Alere (ALR) as a "water-logged and getting wetter" (weak stocks crossing below support with today's range greater than 200%) candidate
Alere Inc. Announces Fourth Quarter 2013 Results
PR Newswire - Thu Feb 06, 6:30AM CST
Alere Inc. (NYSE: ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health information solutions, today announced its financial results for the quarter ended December 31, 2013.
Miraculins and Alere Shift Focus of Endoglin Program from Sub-License to Supply Agreement
Marketwire - Thu Jan 30, 6:52PM CST
Miraculins Inc. (TSX VENTURE: MOM) ("Miraculins" or the "Company"), a medical diagnostic company focused on acquiring, developing and commercializing diagnostic and risk assessment technologies for unmet clinical needs, announces today that Alere Inc. ("Alere") has elected not to proceed further in the direct commercial development of a professional diagnostic product for the biomarker Endoglin, but instead will support Miraculins in seeking commercialization opportunities for Endoglin by supplying key antibodies that were developed by Alere. As part of this decision, Alere has declined to proceed further with its Endoglin license from Miraculins and the parties have agreed to work to enhance Miraculins' rights to receive a secure supply of high quality, proprietary Endoglin reagents manufactured by Alere.
Alere Inc. Schedules Conference Call for 8:30 a.m. ET February 6, 2014 to Discuss Fourth Quarter 2013 Results
PR Newswire - Thu Jan 30, 7:00AM CST
Alere Inc. (NYSE:ALR), a global leader in enabling individuals to take charge of their health at home through the merger of rapid diagnostics and health information solutions, today announced that it will release its fourth quarter 2013 earnings on Thursday, February 6, 2014. The Company will also host a conference call beginning at 8:30 a.m. (Eastern Time) on that date to discuss these results and other corporate matters. During the conference call, the Company will discuss and answer questions concerning business and financial developments and trends. The Company's responses to questions, as well as other matters discussed during the conference call, may contain or constitute information that has not been disclosed previously.
First Rapid Molecular Diagnostic Test to Detect Influenza A and B Virus in Under 15 Minutes Now Available in Europe on the Alere i Platform
PR Newswire - Thu Jan 23, 11:30AM CST
Alere Inc. (NYSE: ALR), a leading global provider of point-of-care rapid diagnostic and health information solutions, today announced the availability in Europe of the Alere i Influenza A & B test, the first and only molecular test to detect and differentiate influenza A and B virus in less than 15 minutes. The test is now commercially available in Austria, France, Spain, Switzerland, Germany, Italy and the UK.
Do You Know How to Read a Report Card?
by Charles Ekyagonza - All Africa Global Media - Fri Jan 17, 1:44AM CST
At the end of every term, learners are given report cards as a way of evaluating their work and behaviour during the term.
